×
About 1,920 results

ALLMedicine™ Hypophosphatemia Center

Research & Reviews  632 results

Factors associated with refeeding hypophosphatemia in adolescents and young adults hosp...
https://doi.org/10.1002/ncp.10772
Nutrition in Clinical Practice : Official Publication of ... Kells M, Gregas M et. al.

Sep 9th, 2021 - Refeeding hypophosphatemia (RH) in individuals with anorexia nervosa (AN) is a potentially fatal complication of nutrition restoration; yet, little is known about risk. This retrospective cohort study examined factors found in hospitalized youth w...

Impact of different hemodiafiltration solutions on ionemia in long-term CRRT.
https://doi.org/10.1177/03913988211043203
The International Journal of Artificial Organs; Nalesso F, Garzotto F et. al.

Sep 3rd, 2021 - Critical patients with Acute Kidney Injury (AKI) requiring renal replacement therapy are in most cases eligible only for continuous modalities where the electrolyte balance control is a critical issue. The standard solutions used for hemodiafiltra...

Autosomal Dominant Hypophosphatemic Rickets: A Case Report and Review of the Literature.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392413
International Journal of Environmental Research and Publi... Mameli C, Sangiorgio A et. al.

Aug 28th, 2021 - Autosomal dominant hypophosphatemic rickets (ADHR) is an extremely rare form of genetic rickets caused by mutations in the fibroblast growth factor 23 gene. ADHR is characterized by hypophosphatemia secondary to isolated renal phosphate wasting. O...

Prevalence of enthesopathies in adults with X-linked hypophosphatemia : analysis of ris...
https://doi.org/10.1210/clinem/dgab580
The Journal of Clinical Endocrinology and Metabolism; Herrou J, Picaud AS et. al.

Aug 19th, 2021 - Enthesopathies are the determinant of a poor quality of life in adults with X-linked hypophosphatemia (XLH). To describe the prevalence of patients with enthesopathies and to identify the risk factors of having enthesopathies. Retrospective study ...

A multicenter randomized clinical trial of pharmacological vitamin B1 administration to...
https://doi.org/10.1016/j.clnu.2021.07.024
Clinical Nutrition (Edinburgh, Scotland); Deane AM, Jiang A et. al.

Aug 14th, 2021 - Hypophosphatemia may be a useful biomarker to identify thiamine deficiency in critically ill enterally-fed patients. The objective was to determine whether intravenous thiamine affects blood lactate, biochemical and clinical outcomes in this group...

see more →

Drugs  87 results see all →

Clinicaltrials.gov  1 results

Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding
https://clinicaltrials.gov/ct2/show/NCT01307007

Feb 19th, 2018 - To assess the safety of an investigational intravenous iron (ferric carboxymaltose [FCM]) or an equal dose of iron dextran and explore the mechanism of hypophosphatemia following administration of FCM or that of an equal dose of iron dextran when ...

see more →

News  48 results

Camidanlumab Tesirine Elicits Encouraging ORR in Heavily Pretreated Hodgkin Lymphoma
https://www.onclive.com/view/camidanlumab-tesirine-elicits-encouraging-orr-in-heavily-pretreated-hodgkin-lymphoma

Jun 22nd, 2021 - Camidanlumab tesirine (ADCT-301) was found to elicit an objective response rate (ORR) of 66.3% in patients with relapsed/refractory Hodgkin lymphoma, according to interim data from a phase 2 study (NCT04052997) presented during the 16th Internatio...

Entinostat Doesn't Overcome Endocrine Resistance in Breast Cancer
https://www.medscape.com/viewarticle/944005

Jan 13th, 2021 - The histone deacetylase (HDAC) inhibitor entinostat failed to overcome resistance to endocrine therapy in hormone receptor–positive, HER2-negative, advanced breast cancer in a phase 3 trial. The study showed no difference in response, progression-...

Positive Safety Profile Reported for Atezolizumab/Axi-Cel Combo in DLBCL
https://www.onclive.com/view/positive-safety-profile-reported-for-atezolizumabaxicel-combo-in-dlbcl

Dec 20th, 2020 - Caron Jacobson, MD A manageable safety profile was observed for the combination of atezolizumab (Tecentriq) and the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, axicabtagene ciloleucel (axi-cel; Yescarta), in patients with refractory...

Tiragolumab/Atezolizumab Shows Early First-in-Human Efficacy in Frontline PD-L1+ NSCLC
https://www.onclive.com/view/tiragolumab-atezolizumab-shows-early-first-in-human-efficacy-in-frontline-pd-l1-nsclc

Dec 20th, 2020 - Tiragolumab in combination with atezolizumab (Tecentriq) demonstrated early clinical activity and was found to be well tolerated in patients with advanced solid tumors, including those with metastatic non–small cell lung cancer (NSCLC) who were PD...

Clinical Trial Reports: October 2007
https://www.onclive.com/view/articles_clinicaltrials_oct2007

Dec 5th, 2020 - %u25BA PHASE III Is Combination or Sequential Treatment for Metastatic Colorectal Cancer More Effective? Optimal treatment of advanced colorectal cancer is still very much a dynamic question. In order to determine whether combination tre...

see more →